Compare Stocks → [BUY ALERT] Our #1 A.I. Stock for March (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AKBANASDAQ:AKCAOTCMKTS:BLUSFOTCMKTS:CYDYNASDAQ:DRNA Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.02-9.8%$1.62$0.49▼$2.48$422.93M0.783.89 million shs43.67 million shsAKCAAkcea Therapeutics$18.17$18.16$8.00▼$21.70$1.85B1.45361,806 shsN/ABLUSFBELLUS Health$9.77$0.49▼$2.60$2.35B1.5539,610 shs3.45 million shsCYDYCytoDyn$0.17+1.0%$0.17$0.15▼$0.42$164.84M0.213.16 million shs1.15 million shsDRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/A5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics+12.00%+15.46%+48.34%+75.00%+273.77%AKCAAkcea Therapeutics0.00%0.00%0.00%0.00%0.00%BLUSFBELLUS Health0.00%0.00%0.00%0.00%+105.87%CYDYCytoDyn+0.97%+3.74%-0.30%-9.06%-55.57%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Grab Your Free Bitcoin Today! (Ad)And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right hereMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.1554 of 5 stars3.53.00.04.03.00.80.6AKCAAkcea TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics3.00Buy$4.50122.77% UpsideAKCAAkcea TherapeuticsN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/ACurrent Analyst RatingsLatest DRNA, BLUSF, AKCA, CYDY, and AKBA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$5.00 ➝ $6.003/15/2024AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$194.62M2.17N/AN/A($0.16) per share-12.63AKCAAkcea Therapeutics$488.54M3.78$0.51 per share35.54$5.78 per share3.14BLUSFBELLUS Health$30K0.00N/AN/A$0.25 per share0.00CYDYCytoDyn$270K610.51N/AN/A($0.12) per share-1.39DRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.28N/AN/AN/A-26.32%N/A-20.36%5/13/2024 (Estimated)AKCAAkcea Therapeutics$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/ABLUSFBELLUS Health-$7.01M-$0.10N/AN/AN/A-49,910.34%-48.37%-45.25%N/ACYDYCytoDyn-$79.82M-$0.06N/A∞N/AN/AN/A-449.49%4/6/2024 (Estimated)DRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/ALatest DRNA, BLUSF, AKCA, CYDY, and AKBA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023AKBAAkebia Therapeutics-$0.04-$0.04N/AN/A$55.64 million$56.20 million1/16/2024Q2 2024CYDYCytoDynN/A-$0.01-$0.01-$0.01N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAKCAAkcea TherapeuticsN/AN/AN/AN/AN/ABLUSFBELLUS HealthN/AN/AN/AN/AN/ACYDYCytoDynN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.181.03AKCAAkcea TherapeuticsN/A12.1711.78BLUSFBELLUS HealthN/A13.8713.87CYDYCytoDynN/A0.070.07DRNADicerna PharmaceuticalsN/A2.462.46OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AKCAAkcea Therapeutics19.27%BLUSFBELLUS HealthN/ACYDYCytoDyn5.06%DRNADicerna Pharmaceuticals78.91%Insider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.84%AKCAAkcea Therapeutics1.50%BLUSFBELLUS Health24.17%CYDYCytoDyn0.71%DRNADicerna Pharmaceuticals10.20%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics204209.37 million201.33 millionOptionableAKCAAkcea Therapeutics248101.60 millionN/AOptionableBLUSFBELLUS Health10159.12 millionN/ANot OptionableCYDYCytoDyn12989.43 million982.41 millionNot OptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableDRNA, BLUSF, AKCA, CYDY, and AKBA HeadlinesSourceHeadlineBoehringer Inks Potential $2B Deal with Ribo, Targets NASH with siRNA Therapiesbiospace.com - January 3 at 1:05 PMBoehringer bets $2B in biobucks to unlock siRNA targets for NASH treatmentsfiercebiotech.com - January 3 at 8:05 AMArrowhead Pharmaceuticals (NASDAQ: ARWR)fool.com - May 25 at 11:01 PM'Mad Money' Lightning Round: I'm Staying Away From Five Belowthestreet.com - February 16 at 10:02 AMBiondVax Pharmaceuticals Stock (NASDAQ:BVXV), Quotes and News Summarybenzinga.com - February 7 at 7:33 AMMyc Proto-Oncogene Protein Market 2023 Statistics, Industry Share, Latest Trends, Growth Drivers, Size Estimate and Forecast till 2028marketwatch.com - January 26 at 2:13 PMWe Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growthfinance.yahoo.com - January 19 at 12:03 AMNews - Dicerna Pharmaceuticals, Denmarkthepharmaletter.com - May 27 at 3:55 PMNovo Nordisk-Dicernafiercepharma.com - January 18 at 12:43 PMDRNA Jan 2022 22.500 callca.finance.yahoo.com - January 14 at 10:32 PMDRNA Jul 2022 40.000 call(CONTRca.finance.yahoo.com - January 14 at 10:32 PMNovo Nordisk Announces Completion of Dicerna Pharmaceuticals Acquisitionfinance.yahoo.com - December 28 at 1:12 PMDicerna Pharmaceuticals EPS Diluted (5 Year Growth)ycharts.com - December 18 at 11:45 PMWhat Direction Does Dicerna Pharmaceuticals Inc. (NASDAQ: DRNA) Analysts Think The Company Will Take?stocksregister.com - December 15 at 7:59 PMShareholders Sue Dicerna Pharmaceuticals Over Proposed Mergerlawstreetmedia.com - December 7 at 9:12 AMwhy Dicerna Pharmaceuticals Inc. [DRNA] is a Good Choice for Investors After New Price Target of $34.96dbtnews.com - November 23 at 3:14 PMDICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNAprnewswire.com - November 19 at 11:46 PMSHAREHOLDER ALERT: WeissLaw LLP Investigates Dicerna Pharmaceuticals, Inc.finance.yahoo.com - November 19 at 1:03 AMDicerna Pharmaceuticals acquired by Novo Nordisk; Shares rocket 80%invezz.com - November 18 at 8:01 PM“The Buzz” Show: Dicerna Pharmaceuticals (NASDAQ: DRNA) Acquisition by Novo Nordiskfinancialbuzz.com - November 18 at 8:01 PMDICERNA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of DRNA and Encourages Investors to Contact the Firmfinance.yahoo.com - November 18 at 3:00 PMSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Dicerna Pharmaceuticals, Inc. to Novo Nordiskfinance.yahoo.com - November 18 at 3:00 PMSHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of Dicerna Pharmaceuticals, Inc.finance.yahoo.com - November 18 at 3:00 PMDicerna Stock Skyrockets as Novo Nordisk to Buy Research Partner for $3.3 Billionbarrons.com - November 18 at 10:00 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAkebia TherapeuticsNASDAQ:AKBAAkebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Akcea TherapeuticsNASDAQ:AKCAAkcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.BELLUS HealthOTCMKTS:BLUSFBELLUS Health, Inc. is a biopharmaceutical development company, which engages in the research and development of products that provide health solutions and address critical unmet medical needs. Its products include BLU-5937, KIACTA, AMO-01, and ALZ-801. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.CytoDynOTCMKTS:CYDYCytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for the treatment of NASH, HIV- NASH, and solid tumors, as well as under pre-clinical development for the treatment of HIV-PrEP and HIV-Cure. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.Dicerna PharmaceuticalsNASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.